For VCs & Investors
A physician (MD) and biomedical engineer (BME) read on the deals that reach diligence — built on a proprietary multi-source substrate, with factual claims cited to their sources. License Vantage as your fund's diligence bench, or run a single deal to see the work first.
We don't forecast outcomes — we make knowable risk legible. The read a senior physician and biomedical engineer would run on a deal, delivered faster and at lower cost than an associate or a banker — and, unlike a generic LLM that can invent sources, with factual claims you can check.
Screening a Pipeline
Run a Quick Screen on each company in your pipeline: six independent signals per company, each linked to its source records, with no composite score and no ranking verdict.
Why Vantage
Get institutional-grade risk assessment without institution-grade timelines or costs
What We Find
Six of the areas a full report reads — where the diligence questions on early-stage medtech most often sit.
Diligence domains per full report
Companies in our substrate
Factual claims cited to their sources
Public data sources
Engineering, manufacturing and quality questions, read from the public record and the materials you provide.
Study design, endpoints and generalizability, read against the trial-registry record.
Predicate strategies and pathway assumptions. A misjudged predicate or pathway can add many months and material cost before a device reaches market.
Patent scope, assignees and the competitive patent landscape, including freedom-to-operate questions to raise with counsel.
Who leads regulatory, clinical and manufacturing work, and which of those roles the record does not show.
Reimbursement pathways and coverage, read from CMS and other federal data.
Licensing & Evaluations
Funds can license Vantage as a standing diligence resource across their deal flow. Prefer to see the work first? Run one deal — the fee credits toward a license if you convert.
Priced to how many deals you run.
Start with one deal
Fund
Platform
Enterprise — priced to your portfolio. For high-volume funds and PE portfolios: an annual report allowance scoped to your portfolio. See portfolio & PE →
The à-la-carte option
A low-commitment proof of capability before you license. A single evaluation's fee credits toward a license if you convert.
Running diligence across a whole portfolio or fund? The Vantage License covers a set number of Quick Screens and Diligence Reports each year. Talk to Arvind Ravinutala, MD →
A single missed clinical, regulatory, or technical risk can cost far more than the diligence that would have surfaced it.
Investment Timeline
Your licensed diligence bench across sourcing, screening, diligence and the investment committee
Quick Screens on inbound deals
Quick Screen on top 10 for rapid triage
Diligence Report with MD debrief on finalists
Diligence Report findings in front of the IC
A fresh Diligence Report before a follow-on round
Methodology in public
Before you trust an investor-grade read, see the framework run on companies whose outcomes are now public. No private claims, no unnamed founders, no rewrites.
Recalls of polyethylene implant components over a packaging defect (2021–22), then Chapter 11 in 2024. We walk the technology and supply-chain questions visible in the public record.
Source: FDA recall notices & 2024 Chapter 11 filings (D. Del.) Read the retrospective →An early FDA-authorized prescription digital therapeutic, a 2021 SPAC listing and a 2023 bankruptcy. We walk the coverage and prescribing-economics questions visible in the public record.
Source: 2021 SPAC merger & 2023 Chapter 11 filings (SEC / D. Del.) Read the retrospective →An October 2021 FDA warning letter, three months after Owlet’s July 2021 SPAC listing, said the Smart Sock was being marketed as an uncleared medical device, and Owlet stopped selling it in the US. We trace the regulatory questions visible in the public record.
Source: FDA warning letter (2021) & public SEC filings Read the retrospective →We don't publish unnamed-client testimonials. When a sponsor allows it, we'll cite them by name. Until then, our work is judged on the rigor and traceability of the methodology you can read end to end.
License Vantage for screening and diligence reports across your fund — or run a single deal to see the work first. The evaluation fee credits toward a license.
10 clinical, regulatory, and technical red flags to check — curated by Arvind Ravinutala, MD and Aswini Ravinutala, BME.
Download the ChecklistNo email required. No paywall.